Article by Sam Riches, Growth Op
Vancouver-based companies Optimi Health and Numinus Wellness are one step closer to conducting clinical trials for psilocybin after submitting an information package to Health Canada.
With the assistance of the Impact Clinical Trials Accelerator at the University of Calgary, the companies announced they had submitted the application for review and comment. If approved, Numinus plans to develop an all-natural psilocybin capsule for use in Optimi’s human clinical trials.
The initial trial would focus on dosage before expanding into psilocybin treatments for a variety of health conditions.
“This is another important step for our commitment to the development of naturally sourced, evidence-based product formulations,” said Optimi chairman of the board JJ Wilson.
The information package included the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from psilocybe mushrooms.
Optimi will retain 100 per cent ownership of the resulting all-natural psilocybin capsule and full intellectual property rights to its use, according to the release.